Unstable angina and non-ST-segment elevation myocardial infarction: part I. Initial evaluation and management, and
Stephen D Wiviott1, Eugene Braunwald
1Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA. swiviott@partners.org
Insights
This guideline provides a framework for managing unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI). It details initial evaluation, hospital care, and medical treatments for these common cardiac conditions.
Area of Science:
- Cardiology
- Clinical Practice Guidelines
Background:
- Unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI) affect over 1 million U.S. hospital admissions annually.
- Standardized management protocols are crucial for effective patient care.
Purpose of the Study:
- To present a comprehensive management guideline for UA/NSTEMI.
- To update and standardize the assessment and treatment strategies for UA/NSTEMI patients.
Main Methods:
- The guideline development involved a task force from the American College of Cardiology and the American Heart Association.
- It synthesizes recent medical advances into a practical clinical tool.
- The management framework includes initial evaluation, hospital care, revascularization, and post-hospital care.
Main Results:
- Initial evaluation utilizes patient history, physical examination, electrocardiogram, and cardiac biomarkers for diagnosis and risk stratification.
- Hospital care emphasizes appropriate triage and monitoring.
- Medical treatment encompasses anti-ischemic, antiplatelet, and antithrombotic therapies.
Conclusions:
- The guideline offers a structured approach to managing UA/NSTEMI, covering critical phases from diagnosis to post-discharge.
- It aims to improve the quality of care for patients with these acute coronary syndromes.
Abstract:
Each year, more than 1 million patients are admitted to U.S. hospitals because of unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI). To help standardize the assessment and treatment of these patients, the American College of Cardiology and the American Heart Association convened a task force to formulate a management guideline. This guideline, which was published in 2000 and updated in 2002, highlights recent medical advances and is a practical tool to help physicians provide medical care for patients with UA/NSTEMI. Management of suspected UA/NSTEMI has four components: initial evaluation and management; hospital care; coronary revascularization; and hospital discharge and post-hospital care. Part I of this two-part article discusses the first two components of management. During the initial evaluation, the history, physical examination, electrocardiogram, and cardiac biomarkers are used to determine the likelihood that the patient has UA/NSTEMI and to aid in risk assessment when the diagnosis is established. Hospital care consists of appropriate initial triage and monitoring. Medical treatment includes anti-ischemic therapy (oxygen, nitroglycerin, beta blocker), antiplatelet therapy (aspirin, clopidogrel, platelet glycoprotein IIb/IIIa inhibitor), and antithrombotic therapy (heparin, low-molecular-weight heparin).
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Angina II: Classification
01:29Angina III: Clinical Manifestations and Assessment
01:20Angina V: Nursing Management